182 related articles for article (PubMed ID: 32758349)
1. [Mechanism of Histologic Transformation of Drive Gene Positive Lung Adenocarcinoma in Targeted Therapy and Treatment Strategy].
Xie T; Li Y; Xing P
Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):701-709. PubMed ID: 32758349
[TBL] [Abstract][Full Text] [Related]
2. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
[TBL] [Abstract][Full Text] [Related]
3. Combined Small and Squamous Transformation in EGFR-mutated Lung Adenocarcinoma.
Hakozaki T; Kitazono M; Takamori M; Kiriu T
Intern Med; 2020 May; 59(10):1291-1294. PubMed ID: 32101830
[TBL] [Abstract][Full Text] [Related]
4. Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma.
Matsumura Y; Umemura S; Ishii G; Tsuta K; Matsumoto S; Aokage K; Hishida T; Yoshida J; Ohe Y; Suzuki H; Ochiai A; Goto K; Nagai K; Tsuchihara K
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2159-70. PubMed ID: 25989941
[TBL] [Abstract][Full Text] [Related]
5. Clinical features of large cell neuroendocrine carcinoma: a population-based overview.
Derks JL; Hendriks LE; Buikhuisen WA; Groen HJ; Thunnissen E; van Suylen RJ; Houben R; Damhuis RA; Speel EJ; Dingemans AM
Eur Respir J; 2016 Feb; 47(2):615-24. PubMed ID: 26541538
[TBL] [Abstract][Full Text] [Related]
6. Small Cell Lung Cancer Derived from Adenocarcinoma with Mutant Epidermal Growth Factor Receptor Provides a Signature of Transcriptional Alteration in Tumor Cells.
Tenjin Y; Nakamura K; Ishizuka S; Saruwatari K; Sato R; Tomita Y; Saeki S; Ichiyasu H; Fujii K; Ito T; Sakagami T
Intern Med; 2019 Nov; 58(22):3261-3265. PubMed ID: 31292388
[TBL] [Abstract][Full Text] [Related]
7. EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs.
Lin CA; Yu SL; Chen HY; Chen HW; Lin SU; Chang CC; Yu CJ; Yang PC; Ho CC
J Thorac Oncol; 2019 Mar; 14(3):513-526. PubMed ID: 30521971
[TBL] [Abstract][Full Text] [Related]
8. Histological Transformation to Large Cell Neuroendocrine Carcinoma from Lung Adenocarcinoma Harboring an EGFR Mutation: An Autopsy Case Report.
Moriya R; Hokari S; Shibata S; Koizumi T; Tetsuka T; Ito K; Hashidate H; Tsukada H
Intern Med; 2017; 56(15):2013-2017. PubMed ID: 28768973
[TBL] [Abstract][Full Text] [Related]
9. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
[TBL] [Abstract][Full Text] [Related]
10. Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review.
Liu Y
Cancer Biol Ther; 2018 Jun; 19(6):445-449. PubMed ID: 29461911
[TBL] [Abstract][Full Text] [Related]
11. Lineage-specific intolerance to oncogenic drivers restricts histological transformation.
Gardner EE; Earlie EM; Li K; Thomas J; Hubisz MJ; Stein BD; Zhang C; Cantley LC; Laughney AM; Varmus H
Science; 2024 Feb; 383(6683):eadj1415. PubMed ID: 38330136
[TBL] [Abstract][Full Text] [Related]
12. Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.
Kita K; Fukuda K; Takahashi H; Tanimoto A; Nishiyama A; Arai S; Takeuchi S; Yamashita K; Ohtsubo K; Otani S; Yanagimura N; Suzuki C; Ikeda H; Tamura M; Matsumoto I; Yano S
Cancer Sci; 2019 Oct; 110(10):3215-3224. PubMed ID: 31432603
[TBL] [Abstract][Full Text] [Related]
13. The clinicopathologic of pulmonary adenocarcinoma transformation to small cell lung cancer.
Yang H; Liu L; Zhou C; Xiong Y; Hu Y; Yang N; Qu J
Medicine (Baltimore); 2019 Mar; 98(12):e14893. PubMed ID: 30896637
[TBL] [Abstract][Full Text] [Related]
14. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
Zhang JT; Li Y; Yan LX; Zhu ZF; Dong XR; Chu Q; Wu L; Zhang HM; Xu CW; Lin G; Yu ZY; Hu J; Zhu B; Wang HJ; Yang F; Song ZB; Han ZB; Li MX; Lin J; Wu YL; Wang JL; Zhong WZ
Lung Cancer; 2020 Jan; 139():118-123. PubMed ID: 31775086
[TBL] [Abstract][Full Text] [Related]
15. Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma.
Watanabe S; Sone T; Matsui T; Yamamura K; Tani M; Okazaki A; Kurokawa K; Tambo Y; Takato H; Ohkura N; Waseda Y; Katayama N; Kasahara K
Lung Cancer; 2013 Nov; 82(2):370-2. PubMed ID: 24012411
[TBL] [Abstract][Full Text] [Related]
16. Progress in the knowledge on the transformation of lung adenocarcinoma to small-cell lung cancer.
Wang A; Han C; Zhao H; Zheng Z; Ye X; Shan R
J Cancer Res Ther; 2023 Feb; 19(1):14-19. PubMed ID: 37006037
[TBL] [Abstract][Full Text] [Related]
17. Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.
Popat S; Wotherspoon A; Nutting CM; Gonzalez D; Nicholson AG; O'Brien M
Lung Cancer; 2013 Apr; 80(1):1-4. PubMed ID: 23312887
[TBL] [Abstract][Full Text] [Related]
18. Histologic transformation of non-small-cell lung cancer in brain metastases.
Jiang M; Zhu X; Han X; Jing H; Han T; Li Q; Ding X
Int J Clin Oncol; 2019 Apr; 24(4):375-384. PubMed ID: 30443811
[TBL] [Abstract][Full Text] [Related]
19. Transformation from EGFR/PTEN co-mutated lung adenocarcinoma to small cell carcinoma in lymph node metastasis.
Hayashi T; Takamochi K; Kohsaka S; Kishikawa S; Suehara Y; Takahashi F; Suzuki K; Saito T; Yao T
Pathol Int; 2020 May; 70(5):295-299. PubMed ID: 32162763
[TBL] [Abstract][Full Text] [Related]
20. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
Sehgal K; Varkaris A; Viray H; VanderLaan PA; Rangachari D; Costa DB
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
